Case Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer
{{output}}
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a... ...
